Opus Genetics, Inc. Announces Issuance of \$50 Million Senior Secured Notes, Strengthening Balance Sheet

Durham, NC, April 24, 2026 — Opus Genetics, Inc. (Nasdaq: IRD), a gene therapy company focused on inherited retinal diseases, has announced a significant financial transaction that may have important implications for shareholders and the company’s future trajectory.

Key Points of the Report

• Issuance of \$50 Million Senior Secured Notes: On April 21, 2026, Opus Genetics issued \$50 million in principal amount of senior secured notes (the “Initial Tranche Notes”) to a syndicate of purchasers, under a Note Purchase Agreement entered into with OPCM LLC as purchaser agent and certain subsidiaries as guarantors.
• Terms of the Notes:
  • The Notes were issued at par value and will mature on April 21, 2033 (a 7-year term).
  • The Notes bear a floating interest rate based on Term SOFR (Secured Overnight Financing Rate), subject to a floor, plus an applicable margin. Interest is payable quarterly.
  • The Notes are senior secured obligations, backed by substantially all assets of Opus Genetics and certain subsidiaries.
  • The obligations under the Notes are guaranteed by certain subsidiaries of the company.
• Event of Default Provisions: The Notes include customary events of default, including payment defaults, covenant breaches, insolvency events, and certain material adverse events. In the event of default, the obligations may be accelerated.
• Balance Sheet Impact: The new capital injection bolsters Opus Genetics’ cash position, potentially providing financial flexibility to advance its clinical pipeline and strategic initiatives.
• Trading Information: Opus Genetics’ common stock trades on The Nasdaq Stock Market LLC under the ticker symbol IRD.

Why This Matters for Shareholders

• Potential Share Price Impact: The \$50 million capital raise through a senior secured debt facility is a significant event. It provides the company with substantial liquidity, which may be used for advancing clinical trials, business development, or general corporate purposes. The improved liquidity position could be viewed positively by investors, as it reduces near-term financial risks and demonstrates lender confidence in Opus Genetics’ business prospects.
• Leverage and Financial Risk: By taking on senior secured debt, the company increases its leverage. While the terms appear standard, shareholders should note that these notes are secured by most company assets and come with covenants and default provisions. In the event of financial distress, noteholders would have significant claims on company assets.
• Not an Emerging Growth Company: The report confirms Opus Genetics is no longer classified as an emerging growth company, which may affect its reporting requirements and regulatory obligations.

Other Corporate Details

• Company Name: Opus Genetics, Inc. (formerly Ocuphire Pharma, Inc. and Rexahn Pharmaceuticals, Inc.)
• Principal Executive Offices: 8 Davis Drive, Suite 220, Durham, NC 27713
• Phone: (984) 884-6030
• Fiscal Year End: December 31
• Standard Industrial Classification: Pharmaceutical Preparations (2834)

Conclusion

The \$50 million senior secured note issuance is a material development for Opus Genetics, Inc. shareholders. It strengthens the company’s balance sheet and provides resources for future growth but introduces new debt obligations and associated covenants. Investors should monitor how management deploys this capital and any further disclosures about the use of proceeds, as these may further impact the company’s valuation and share price.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should review all available information and consult with their financial advisor before making investment decisions. The author and publisher are not liable for any losses resulting from investment activities based on this report.

View Opus Genetics, Inc. Historical chart here